Inventor · disambiguated record
Martin Devenport
Also filed as: DEVENPORT MARTIN
12 granted patents·14 pending applications·20 citations·filing 2016–2025
85Inventor score
Top patents by PatentIndex Score
26 records- 0195US10618960B2Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereofONCOIMMUNE INC·Filed 2016·Granted Apr 14, 2020·12 cites·14 claims
- 0293US12227557B2CD80 and CD86 binding protein compositions and uses thereofONCOC4 INC·Filed 2022·Granted Feb 18, 2025·2 cites·20 claims
- 0386US11261233B2CD80 and CD86 binding protein compositions and uses thereofONCOC4 INC·Filed 2017·Granted Mar 1, 2022·6 cites·19 claims
- 0479US12473362B2Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereofONCOC4 INC·Filed 2023·Granted Nov 18, 2025·0 cites·12 claims
- 0576US12441780B2CD80 and CD86 binding protein compositions and uses thereofONCOC4 INC·Filed 2022·Granted Oct 14, 2025·0 cites·17 claims
- 0674US2025043003A1Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effectsONCOC4 INC·Filed 2024·Application pending·0 cites
- 0767US11629188B2Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereofONCOC4 INC·Filed 2020·Granted Apr 18, 2023·0 cites·12 claims
- 0863US12129299B2Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effectsONCOC4 INC·Filed 2019·Granted Oct 29, 2024·0 cites·6 claims
- 0963US2025333532A1Glycan-shielded cd24 epitopes and uses thereofONCOC4 INC·Filed 2025·Application pending·0 cites
- 1063US2025243292A1Anti-cd24 compositions and uses thereofONCOC4 INC·Filed 2025·Application pending·0 cites
- 1163US2022098278A1Methods of Use of Soluble CD24 for Neuroprotection and RemyelinationONCOLMMUNE INC·Filed 2021·Application pending·0 cites
- 1259US11571461B2Methods of use of soluble CD24 for treating lupus nephritisONCOIMMUNE INC·Filed 2018·Granted Feb 7, 2023·0 cites·11 claims
- 1358US12286485B2Anti-CD24 compositions and uses thereofONCOC4 INC·Filed 2019·Granted Apr 29, 2025·0 cites·13 claims
- 1458US2024139280A1Use of hif-1-alpha inhibitors in cancer immunotherapyONCOC4 INC·Filed 2022·Application pending·0 cites
- 1558US2021162006A1Use of CD24 Proteins for Treating Leptin-Deficient ConditionsONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 1658US2024218067A1Anti-siglec compositions and uses thereofONCOC4 INC·Filed 2022·Application pending·0 cites
- 1757US10799558B2Use of CD24 proteins for treating leptin-deficient conditionsONCOIMMUNE INC·Filed 2017·Granted Oct 13, 2020·0 cites·19 claims
- 1857US2025257117A1Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancerONCOC4 INC·Filed 2023·Application pending·0 cites
- 1954US11911441B2Methods of use of CD24 for the prevention and treatment of leukemia relapseONCOIMMUNE INC·Filed 2019·Granted Feb 27, 2024·0 cites·16 claims
- 2052US2023108492A1Methods of use of soluble cd24 for treating viral pneumoniaONCOIMMUNE INC·Filed 2021·Application pending·0 cites
- 2150US2020181235A1Methods of use of soluble cd24 for neuroprotection and remyelinationONCOIMMUNE INC·Filed 2018·Application pending·0 cites
- 2248US2023103352A1Methods of use of soluble cd24 for treating sars-cov-2 infectionONCOIMMUNE INC·Filed 2021·Application pending·0 cites
- 2346US11547741B2Methods of use of soluble CD24 for treating immune related adverse events in cancer therapiesONCOIMMUNE INC·Filed 2018·Granted Jan 10, 2023·0 cites·16 claims
- 2446US2022000974A1Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or DiabetesONCOLMMUNE INC·Filed 2020·Application pending·0 cites
- 2545US2022000973A1Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic SteatohepatitisONCOLMMUNE INC·Filed 2020·Application pending·0 cites
- 2645US2021047410A1Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapyONCOLMMUNE INC·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →